Rafael Ramirez-Carracedo
Overview
Explore the profile of Rafael Ramirez-Carracedo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
127
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ramirez-Carracedo R, Hernandez I, Moreno-Gomez-Toledano R, Diez-Mata J, Tesoro L, Gonzalez-Cucharero C, et al.
J Hypertens
. 2024 Feb;
42(4):685-693.
PMID: 38406874
Background: Endothelial nitric oxide synthase (NOS3) elicits atheroprotection by preventing extracellular matrix (ECM) proteolytic degradation through inhibition of extracellular matrix metalloproteinase inducer (EMMPRIN) and collagenase MMP-13 by still unknown mechanisms....
2.
Moreno-Gomez-Toledano R, Delgado-Marin M, Cook-Calvete A, Gonzalez-Cucharero C, Alcharani N, Jimenez-Guirado B, et al.
World J Diabetes
. 2023 Sep;
14(8):1301-1313.
PMID: 37664470
Background: Diabetes mellitus (DM) is one of the largest global health emergencies of the 21st century. In recent years, its connection with environmental pollutants, such as bisphenol A (BPA), has...
3.
Tesoro L, Hernandez I, Ramirez-Carracedo R, Diez-Mata J, Alcharani N, Jimenez-Guirado B, et al.
Pharmaceutics
. 2022 Oct;
14(10).
PMID: 36297479
(1) Background: Early response after acute myocardial infarction (AMI) prevents extensive cardiac necrosis, in which inflammation resolution, including expression of anti-inflammatory interleukin-10 (IL-10), may play a key role. (2) Methods:...
4.
Ramirez-Carracedo R, Sanmartin M, Ten A, Hernandez I, Tesoro L, Diez-Mata J, et al.
Circ Cardiovasc Imaging
. 2022 Jun;
15(6):e013379.
PMID: 35678191
Background: Rapid screening and accurate diagnosis of acute myocardial infarction are critical to reduce the progression of myocardial necrosis, in which proteolytic degradation of myocardial extracellular matrix plays a major...
5.
Moreno-Gomez-Toledano R, Sanchez-Esteban S, Cook A, Minguez-Moratinos M, Ramirez-Carracedo R, Reventun P, et al.
Biomolecules
. 2021 Oct;
11(10).
PMID: 34680063
Bisphenol A (BPA) is a widespread endocrine disruptor affecting many organs and systems. Previous work in our laboratory demonstrated that BPA could induce death due to necroptosis in murine aortic...
6.
Hernandez I, Tesoro L, Ramirez-Carracedo R, Diez-Mata J, Sanchez S, Saura M, et al.
Int J Mol Sci
. 2021 Apr;
22(6).
PMID: 33809359
In response to cardiac ischemia/reperfusion, proteolysis mediated by extracellular matrix metalloproteinase inducer (EMMPRIN) and its secreted ligand cyclophilin-A (CyPA) significantly contributes to cardiac injury and necrosis. Here, we aimed to...
7.
Tesoro L, Ramirez-Carracedo R, Hernandez I, Diez-Mata J, Pascual M, Saura M, et al.
Rev Esp Cardiol (Engl Ed)
. 2020 Nov;
74(12):1062-1071.
PMID: 33132099
Introduction And Objectives: Ivabradine reduces heart rate by blocking the I(f) current and preserves blood pressure and stroke volume through unknown mechanisms. Caveolin-3 protects the heart by forming protein complexes...
8.
Zaragoza C, Saura M, Ramirez-Carracedo R
Rev Esp Cardiol (Engl Ed)
. 2020 Oct;
74(2):124-125.
PMID: 33077412
No abstract available.
9.
Ramirez-Carracedo R, Tesoro L, Hernandez I, Diez-Mata J, Botana L, Saura M, et al.
Int J Mol Sci
. 2020 Sep;
21(18).
PMID: 32911752
Ivabradine can reduce heart rate through inhibition of the current I() by still unexplored mechanisms. In a porcine model of ischemia reperfusion (IR), we found that treatment with 0.3 mg/kg...
10.
Ramirez-Carracedo R, Tesoro L, Hernandez I, Diez-Mata J, Pineiro D, Hernandez-Jimenez M, et al.
Biomolecules
. 2020 Aug;
10(8).
PMID: 32784904
Toll-like receptor 4 (TLR4) contributes to the pathogenesis of coronary ischemia/reperfusion (IR). To test whether the new TLR4 antagonist, ApTOLL, may prevent coronary IR damage, we administered 0.078 mg/kg ApTOLL...